NFKB1 and cardiac hypertrophy: A previous study found that the NF‐κB inhibitor BAY11‐7082 strongly decreased infarct size and enhanced myocardial function by reducing inflammation and apoptosis.54 Moreover, Li et al found that pre‐treatment with CGA could inhibit iso‐induced cardiac hypertrophy through blocking NF‐κB signalling pathway.